Nakagawa Kazuhiko

J-GLOBAL         Last updated: Aug 28, 2019 at 16:43
 
Avatar
Name
Nakagawa Kazuhiko
Affiliation
Kindai University
Section
Faculty of Medicine
Job title
Professor
Degree
医学博士

Research Interests

 
 

Research Areas

 
 

Education

 
 
 - 
1983
Faculty of Medicine, Kumamoto University
 

Published Papers

 
Udagawa H, Akamatsu H, Tanaka K, Takeda M, Kanda S, Kirita K, Teraoka S, Nakagawa K, Fujiwara Y, Yasuda I, Okubo S, Shintani M, Kosloski MP, Scripture C, Tamura T, Okamoto I
Lung cancer (Amsterdam, Netherlands)   135 145-150   Sep 2019   [Refereed]
Nonagase Y, Takeda M, Azuma K, Hayashi H, Haratani K, Tanaka K, Yonesaka K, Ishii H, Hoshino T, Nakagawa K
Thoracic cancer      Aug 2019   [Refereed]
Sakai K, Takeda M, Shimizu S, Takahama T, Yoshida T, Watanabe S, Iwasa T, Yonesaka K, Suzuki S, Hayashi H, Kawakami H, Nonagase Y, Tanaka K, Tsurutani J, Saigoh K, Ito A, Mitsudomi T, Nakagawa K, Nishio K
Scientific reports   9(1) 11340   Aug 2019   [Refereed]
Corral J, Mok TS, Nakagawa K, Rosell R, Lee KH, Migliorino MR, Pluzanski A, Linke R, Devgan G, Tan W, Quinn S, Wang T, Wu YL
Future oncology (London, England)   15(24) 2795-2805   Aug 2019   [Refereed]
Hayashi H, Nishio K, Nakagawa K
Journal of clinical oncology : official journal of the American Society of Clinical Oncology   37(23) 2090   Aug 2019   [Refereed]
Horinouchi H, Nishio M, Hida T, Nakagawa K, Sakai H, Nogami N, Atagi S, Takahashi T, Saka H, Takenoyama M, Katakami N, Tanaka H, Takeda K, Satouchi M, Isobe H, Maemondo M, Goto K, Hirashima T, Minato K, Sumiyoshi N, Tamura T
Cancer medicine      Jul 2019   [Refereed]
Akamatsu H, Teraoka S, Morita S, Katakami N, Tachihara M, Daga H, Yamamoto N, Nakagawa K
Clinical lung cancer   20(4) e492-e494   Jul 2019   [Refereed]
Watanabe S, Otani T, Iwasa T, Takahama T, Takeda M, Sakai K, Nishio K, Ito A, Nakagawa K
Clinical breast cancer      Jun 2019   [Refereed]
Kimura T, Kawaguchi T, Chiba Y, Yoshioka H, Watanabe K, Kijima T, Kogure Y, Oguri T, Yoshimura N, Niwa T, Kasai T, Hayashi H, Ono A, Asai K, Tanaka H, Yano S, Yamamoto N, Nakanishi Y, Nakagawa K
Japanese journal of clinical oncology      Jun 2019   [Refereed]
Okada M, Kijima T, Aoe K, Kato T, Fujimoto N, Nakagawa K, Takeda Y, Hida T, Kanai K, Imamura F, Oizumi S, Takahashi T, Takenoyama M, Tanaka H, Hirano J, Namba Y, Ohe Y
Clinical cancer research : an official journal of the American Association for Cancer Research      Jun 2019   [Refereed]
Park K, Bennouna J, Boyer M, Hida T, Hirsh V, Kato T, Lu S, Mok T, Nakagawa K, O'Byrne K, Paz-Ares L, Schuler M, Sibilot DM, Tan EH, Tanaka H, Wu YL, Yang JC, Zhang L, Zhou C, Märten A, Tang W, Yamamoto N
Lung cancer (Amsterdam, Netherlands)   132 126-131   Jun 2019   [Refereed]
Nishio M, Nakagawa K, Mitsudomi T, Yamamoto N, Tanaka T, Kuriki H, Zeaiter A, Tamura T
Lung cancer (Amsterdam, Netherlands)   132 160   Jun 2019   [Refereed]
Watanabe S, Yoshioka H, Sakai H, Hotta K, Takenoyama M, Yamada K, Sugawara S, Takiguchi Y, Hosomi Y, Tomii K, Niho S, Yamamoto N, Nishio M, Ohe Y, Kato T, Takahashi T, Kamada A, Suzukawa K, Omori Y, Enatsu S, Nakagawa K, Tamura T
Lung cancer (Amsterdam, Netherlands)   132 157-158   Jun 2019   [Refereed]
Takeda M, Sakai K, Takahama T, Fukuoka K, Nakagawa K, Nishio K
Cancers   11(6)    May 2019   [Refereed]
Takegawa N, Tsurutani J, Kawakami H, Yonesaka K, Kato R, Haratani K, Hayashi H, Takeda M, Nonagase Y, Maenishi O, Nakagawa K
International journal of cancer      May 2019   [Refereed]
Akamatsu H, Koh Y, Okamoto I, Fujimoto D, Bessho A, Azuma K, Morita S, Yamamoto N, Nakagawa K
Lung cancer (Amsterdam, Netherlands)   131 128-133   May 2019   [Refereed]
Zhou Q, Wu YL, Corral J, Nakagawa K, Garon EB, Sbar EI, Wang T, Sandin R, Noonan K, Gernhardt D, Mok TS
Future oncology (London, England)   15(13) 1481-1491   May 2019   [Refereed]
Sugawara S, Nakagawa K, Yamamoto N, Nokihara H, Ohe Y, Nishio M, Takahashi T, Goto K, Maemondo M, Ichinose Y, Seto T, Sakai H, Gemma A, Imamura F, Shingyoji M, Saka H, Inoue A, Takeda K, Okamoto I, Kiura K, Morita S, Tamura T
International journal of clinical oncology   24(5) 485-493   May 2019   [Refereed]
Watanabe S, Yoshioka H, Sakai H, Hotta K, Takenoyama M, Yamada K, Sugawara S, Takiguchi Y, Hosomi Y, Tomii K, Niho S, Yamamoto N, Nishio M, Ohe Y, Kato T, Takahashi T, Kamada A, Suzukawa K, Omori Y, Enatsu S, Nakagawa K, Tamura T
Lung cancer (Amsterdam, Netherlands)   129 55-62   Mar 2019   [Refereed]
Suzuki S, Haratani K, Takahama T, Watanabe S, Takegawa N, Hayashi H, Takeda M, Yonesaka K, Nakagawa K
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer   14(3) e50-e52   Mar 2019   [Refereed]
Watanabe S, Yonesaka K, Tanizaki J, Nonagase Y, Takegawa N, Haratani K, Kawakami H, Hayashi H, Takeda M, Tsurutani J, Nakagawa K
Cancer medicine   8(3) 1258-1268   Mar 2019   [Refereed]
Hayashi H, Kurata T, Takiguchi Y, Arai M, Takeda K, Akiyoshi K, Matsumoto K, Onoe T, Mukai H, Matsubara N, Minami H, Toyoda M, Onozawa Y, Ono A, Fujita Y, Sakai K, Koh Y, Takeuchi A, Ohashi Y, Nishio K, Nakagawa K
Journal of clinical oncology : official journal of the American Society of Clinical Oncology   37(7) 570-579   Mar 2019   [Refereed]
Nishio M, Takahashi T, Yoshioka H, Nakagawa K, Fukuhara T, Yamada K, Ichiki M, Tanaka H, Seto T, Sakai H, Kasahara K, Satouchi M, Han SR, Noguchi K, Shimamoto T, Kato T
Cancer science   110(3) 1012-1020   Mar 2019   [Refereed]
Akamatsu H, Teraoka S, Koh Y, Yamanaka T, Yamamoto N, Nakagawa K
Clinical lung cancer   20(2) 139-141   Mar 2019   [Refereed]
Yonesaka K, Kobayashi Y, Hayashi H, Chiba Y, Mitsudomi T, Nakagawa K
Oncology reports   41(2) 1059-1066   Feb 2019   [Refereed]
Ueda H, Kawakami H, Nonagase Y, Takegawa N, Okuno T, Takahama T, Takeda M, Chiba Y, Tamura T, Nakagawa K
The oncologist   24(2) 163-e76   Feb 2019   [Refereed]
Yonesaka K, Takegawa N, Watanabe S, Haratani K, Kawakami H, Sakai K, Chiba Y, Maeda N, Kagari T, Hirotani K, Nishio K, Nakagawa K
Oncogene   38(9) 1398-1409   Feb 2019   [Refereed]
Sakai H, Takeda M, Sakai K, Nakamura Y, Ito A, Hayashi H, Tanaka K, Nishio K, Nakagawa K
Lung cancer (Amsterdam, Netherlands)   127 59-65   Jan 2019   [Refereed]
Takeda M, Nakagawa K
International journal of molecular sciences   20(1)    Jan 2019   [Refereed]
Ohe Y, Imamura F, Nogami N, Okamoto I, Kurata T, Kato T, Sugawara S, Ramalingam SS, Uchida H, Hodge R, Vowler SL, Walding A, Nakagawa K
Japanese journal of clinical oncology   49(1) 29-36   Jan 2019   [Refereed]
Watanabe S, Hayashi H, Haratani K, Shimizu S, Tanizaki J, Sakai K, Kawakami H, Yonesaka K, Tsurutani J, Togashi Y, Nishio K, Ito A, Nakagawa K
Cancer science   110(1) 52-60   Jan 2019   [Refereed]
Nogami N, Nishio M, Okamoto I, Enatsu S, Suzukawa K, Takai H, Nakagawa K, Tamura T
Respiratory investigation   57(1) 27-33   Jan 2019   [Refereed]
Akamatsu H, Harada H, Tokunaga S, Yoshimura N, Ikeda H, Oizumi S, Sugimoto N, Takano T, Murakami H, Nishimura Y, Yamamoto N, Nakagawa K
Clinical lung cancer   20(1) e25-e27   Jan 2019   [Refereed]
Takeda M, Sakai K, Nishio K, Nakagawa K
OncoTargets and therapy   12 5355-5358   2019   [Refereed]
Kishi K, Sakai H, Seto T, Kozuki T, Nishio M, Imamura F, Nokihara H, Satouchi M, Nakagawa S, Tahata T, Nakagawa K
Cancer treatment and research communications   18 100113   2019   [Refereed]
Sakurai T, Komeda Y, Nagai T, Kamata K, Minaga K, Yamao K, Takenaka M, Hagiwara S, Watanabe T, Nishida N, Kashida H, Nakagawa K, Kudo M
Digestion   1-9   Dec 2018   [Refereed]
Kato R, Hayashi H, Sano K, Handa K, Kumode T, Ueda H, Okuno T, Kawakami H, Matsumura I, Kudo M, Nakagawa K
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer   13(12) e239-e241   Dec 2018   [Refereed]
Mizutani T, Ando M, Mizusawa J, Nakamura K, Fukuda H, Tsukada H, Abe T, Takeda K, Yokoyama A, Nakamura S, Nakagawa K, Yamamoto N, Ohe Y
Journal of geriatric oncology   9(6) 583-588   Nov 2018   [Refereed]
Yamamoto N, Kenmotsu H, Goto K, Takeda K, Kato T, Takeda M, Horinouchi H, Saito I, Sarashina A, Tanaka T, Morsli N, Nakagawa K
Cancer chemotherapy and pharmacology   82(4) 685-694   Oct 2018   [Refereed]
Tanaka F, Yokomise H, Soejima T, Uramoto H, Yamanaka T, Nakagawa K, Yamamoto N, Nishimura Y, Niwa H, Okada M, Nakagawa T, Yamashita M
The Annals of thoracic surgery   106(4) 1018-1024   Oct 2018   [Refereed]
Sasaki T, Seto T, Yamanaka T, Kunitake N, Shimizu J, Kodaira T, Nishio M, Kozuka T, Takahashi T, Harada H, Yoshimura N, Tsutsumi S, Kitajima H, Kataoka M, Ichinose Y, Nakagawa K, Nishimura Y, Yamamoto N, Nakanishi Y
British journal of cancer   119(6) 675-682   Sep 2018   [Refereed]
Furuse J, Kurata T, Okano N, Fujisaka Y, Naruge D, Shimizu T, Kitamura H, Iwasa T, Nagashima F, Nakagawa K
Cancer chemotherapy and pharmacology   82(3) 511-519   Sep 2018   [Refereed]
Murakami H, Nokihara H, Hayashi H, Seto T, Park K, Azuma K, Tsai CM, Yang JC, Nishio M, Kim SW, Kiura K, Inoue A, Takeda K, Kang JH, Nakagawa T, Takeda K, Akazawa R, Kaneko Y, Shimazaki M, Morita S, Fukuoka M, Nakagawa K
Cancer science   109(9) 2852-2862   Sep 2018   [Refereed]
Atagi S, Mizusawa J, Ishikura S, Takahashi T, Okamoto H, Tanaka H, Goto K, Nakagawa K, Harada M, Takeda Y, Nogami N, Fujita Y, Kasai T, Kishi K, Sawa T, Takeda K, Tomii K, Satouchi M, Seto T, Ohe Y
Clinical lung cancer   19(5) e619-e627   Sep 2018   [Refereed]
Sakai H, Tsurutani J, Iwasa T, Komoike Y, Sakai K, Nishio K, Nakagawa K
Breast cancer (Tokyo, Japan)   25(5) 605-613   Sep 2018   [Refereed]
Reungwetwattana T, Nakagawa K, Cho BC, Cobo M, Cho EK, Bertolini A, Bohnet S, Zhou C, Lee KH, Nogami N, Okamoto I, Leighl N, Hodge R, McKeown A, Brown AP, Rukazenkov Y, Ramalingam SS, Vansteenkiste J
Journal of clinical oncology : official journal of the American Society of Clinical Oncology   JCO2018783118   Aug 2018   [Refereed]
Mok TS, Cheng Y, Zhou X, Lee KH, Nakagawa K, Niho S, Lee M, Linke R, Rosell R, Corral J, Migliorino MR, Pluzanski A, Sbar EI, Wang T, White JL, Wu YL
Journal of clinical oncology : official journal of the American Society of Clinical Oncology   36(22) 2244-2250   Aug 2018   [Refereed]
Azuma K, Nishio M, Hayashi H, Kiura K, Satouchi M, Sugawara S, Hida T, Iwamoto Y, Inoue A, Takeda K, Ikeda S, Nakagawa T, Takeda K, Asahina S, Komatsu K, Morita S, Fukuoka M, Nakagawa K
Cancer science   109(8) 2532-2538   Aug 2018   [Refereed]
Solomon BJ, Kim DW, Wu YL, Nakagawa K, Mekhail T, Felip E, Cappuzzo F, Paolini J, Usari T, Tang Y, Wilner KD, Blackhall F, Mok TS
Journal of clinical oncology : official journal of the American Society of Clinical Oncology   36(22) 2251-2258   Aug 2018   [Refereed]
Takano T, Tsurutani J, Takahashi M, Yamanaka T, Sakai K, Ito Y, Fukuoka J, Kimura H, Kawabata H, Tamura K, Matsumoto K, Aogi K, Sato K, Nishio K, Nakagawa K, Saeki T
Breast (Edinburgh, Scotland)   40 67-75   Aug 2018   [Refereed]
Nakatani Y, Kawakami H, Ichikawa M, Yamamoto S, Otsuka Y, Mashiko A, Takashima Y, Ito A, Nakagawa K, Arima S
Investigational new drugs   36(4) 726-731   Aug 2018   [Refereed]
Nishio M, Nakagawa K, Mitsudomi T, Yamamoto N, Tanaka T, Kuriki H, Zeaiter A, Tamura T
Lung cancer (Amsterdam, Netherlands)   121 37-40   Jul 2018   [Refereed]
Haratani K, Hayashi H, Nakagawa K
JAMA oncology   4(7) 1017-1018   Jul 2018   [Refereed]
Nishio M, Kim DW, Wu YL, Nakagawa K, Solomon BJ, Shaw AT, Hashigaki S, Ohki E, Usari T, Paolini J, Polli A, Wilner KD, Mok T
Cancer research and treatment : official journal of Korean Cancer Association   50(3) 691-700   Jul 2018   [Refereed]
Nonagase Y, Takeda M, Tanaka K, Hayashi H, Iwasa T, Nakagawa K
Oncotarget   9(50) 29532-29535   Jun 2018   [Refereed]
Yonesaka K, Haratani K, Takamura S, Sakai H, Kato R, Takegawa N, Takahama T, Tanaka K, Hayashi H, Takeda M, Kato S, Maenishi O, Sakai K, Chiba Y, Okabe T, Kudo K, Hasegawa Y, Kaneda H, Yamato M, Hirotani K, Miyazawa M, Nishio K, Nakagawa K
Clinical cancer research : an official journal of the American Association for Cancer Research   24(11) 2653-2664   Jun 2018   [Refereed]
Fujiwara Y, Takeda M, Yamamoto N, Nakagawa K, Nosaki K, Toyozawa R, Abe C, Shiga R, Nakamaru K, Seto T
Oncotarget   9(34) 23729-23737   May 2018   [Refereed]
Makuuchi Y, Hayashi H, Haratani K, Tanizaki J, Tanaka K, Takeda M, Sakai K, Shimizu S, Ito A, Nishio K, Nakagawa K
Oncotarget   9(33) 23315-23319   May 2018   [Refereed]
Tanizaki J, Chiba Y, Haratani K, Hayashi H, Nakagawa K
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer   13(5) e86-e87   May 2018   [Refereed]
Reck M, Garon EB, Paz-Ares L, Ponce S, Jaime JC, Juan O, Nadal E, Kiura K, Widau RC, He S, Dalal R, Lee P, Nakagawa K
Clinical lung cancer   19(3) 213-220.e4   May 2018   [Refereed]
Takeda M, Sakai K, Hayashi H, Tanaka K, Tanizaki J, Takahama T, Haratani K, Nishio K, Nakagawa K
Oncotarget   9(30) 21132-21140   Apr 2018   [Refereed]
Saka H, Oki M, Kitagawa C, Kogure Y, Kojima Y, Saito AM, Ishida A, Miyazawa T, Takeda K, Nakagawa K, Sasada S, Negoro S
Japanese journal of clinical oncology   48(4) 376-381   Apr 2018   [Refereed]
Kiura K, Imamura F, Kagamu H, Matsumoto S, Hida T, Nakagawa K, Satouchi M, Okamoto I, Takenoyama M, Fujisaka Y, Kurata T, Ito M, Tokushige K, Hatano B, Nishio M
Japanese journal of clinical oncology   48(4) 367-375   Apr 2018   [Refereed]
Okamoto I, Morita S, Tashiro N, Imamura F, Inoue A, Seto T, Yamamoto N, Ohe Y, Nakagawa K, Fukuoka M
Lung cancer (Amsterdam, Netherlands)   117 14-19   Mar 2018   [Refereed]
Haratani K, Hayashi H, Chiba Y, Kudo K, Yonesaka K, Kato R, Kaneda H, Hasegawa Y, Tanaka K, Takeda M, Nakagawa K
JAMA oncology   4(3) 374-378   Mar 2018   [Refereed]
Tanizaki J, Haratani K, Hayashi H, Chiba Y, Nakamura Y, Yonesaka K, Kudo K, Kaneda H, Hasegawa Y, Tanaka K, Takeda M, Ito A, Nakagawa K
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer   13(1) 97-105   Jan 2018   [Refereed]
Treatment of EGFR mutation-positive non-small cell lung cancer complicated by Trousseau syndrome with gefitinib followed by osimertinib: a case report.
Nonagase Y, Takeda M, Tanaka K, Hayashi H, Iwasa T, Nakagawa K.
Oncotarget.   9(50) 29532-29535   2018   [Refereed]
Safety and pharmacokinetics of DS-6051b in Japanese patients with non-small cell lung cancer harboring ROS1 fusions: a phase I study.
Fujiwara Y, Takeda M, Yamamoto N, Nakagawa K, Nosaki K, Toyozawa R, Abe C, Shiga R, Nakamaru K, Seto T.
Oncotarget.   9(34) 23729-23737   2018   [Refereed]
Clinical characteristics of non-small cell lung cancer harboring mutations in exon 20 of EGFR or HER2.
Takeda M, Sakai K, Hayashi H, Tanaka K, Tanizaki J, Takahama T, Haratani K, Nishio K, Nakagawa K.
Oncotarget.   9(30) 21132-21140   2018   [Refereed]
Saka H, Oki M, Kitagawa C, Kogure Y, Kojima Y, Saito AM, Ishida A, Miyazawa T, Takeda K, Nakagawa K, Sasada S, Negoro S
Jpn J Clin Oncol.   48(4) 376-381   2018   [Refereed]
Garassino MC, Cho BC, Kim JH, Mazi?res J, Vansteenkiste J, Lena H, Corral Jaime J, Gray JE, Powderly J, Chouaid C, Bidoli P, Wheatley-Price P, Park K, Soo RA, Huang Y, Wadsworth C, Dennis PA, Rizvi NA; ATLANTIC Investigators.
Lancet Oncol.   19(4) 521-536   2018   [Refereed]
Crizotinib Versus Chemotherapy in Asian Patients with Advanced ALK-positive Non-small Cell Lung Cancer.
Nishio M, Kim DW, Wu YL, Nakagawa K, Solomon BJ, Shaw AT, Hashigaki S, Ohki E, Usari T, Paolini J, Polli A, Wilner KD, Mok T.
Cancer Res Treat.   50(3) 691-700   2018   [Refereed]
Mok TSK, Kim SW, Wu YL, Nakagawa K, Yang JJ, Ahn MJ, Wang J, Yang JC, Lu Y, Atagi S, Ponce S, Shi X, Rukazenkov Y, Haddad V, Thress KS, Soria JC
Journal of clinical oncology : official journal of the American Society of Clinical Oncology   35(36) 4027-4034   Dec 2017   [Refereed]
Wu YL, Cheng Y, Zhou X, Lee KH, Nakagawa K, Niho S, Tsuji F, Linke R, Rosell R, Corral J, Migliorino MR, Pluzanski A, Sbar EI, Wang T, White JL, Nadanaciva S, Sandin R, Mok TS
The Lancet. Oncology   18(11) 1454-1466   Nov 2017   [Refereed]
Kubota K, Yoshioka H, Oshita F, Hida T, Yoh K, Hayashi H, Kato T, Kaneda H, Yamada K, Tanaka H, Ichinose Y, Park K, Cho EK, Lee KH, Lin CB, Yang JC, Hara K, Asato T, Nakagawa K
Journal of clinical oncology : official journal of the American Society of Clinical Oncology   35(32) 3662-3670   Nov 2017   [Refereed]
Watanabe S, Yoshida T, Kawakami H, Takegawa N, Tanizaki J, Hayashi H, Takeda M, Yonesaka K, Tsurutani J, Nakagawa K
Molecular cancer therapeutics   16(11) 2563-2571   Nov 2017   [Refereed]
Hayashi H, Chiba Y, Sakai K, Fujita T, Yoshioka H, Sakai D, Kitagawa C, Naito T, Takeda K, Okamoto I, Mitsudomi T, Kawakami Y, Nishio K, Nakamura S, Yamamoto N, Nakagawa K
Clinical lung cancer   18(6) 719-723   Nov 2017   [Refereed]
Kato R, Hayashi H, Chiba Y, Tanaka K, Takeda M, Nakagawa K
Clinical lung cancer   18(6) e449-e455   Nov 2017   [Refereed]
Ueda H, Takeda M, Ueda S, Kawakami H, Okuno T, Takegawa N, Hayashi H, Tsurutani J, Tamura T, Ishikawa K, Nishimura Y, Nakagawa K
Oncotarget   8(46) 80286-80294   Oct 2017   [Refereed]
Matsuoka H, Tsurutani J, Chiba Y, Fujita Y, Terashima M, Yoshida T, Sakai K, Otake Y, Koyama A, Nishio K, Nakagawa K
BMC cancer   17(1) 674   Oct 2017   [Refereed]
Matsuoka H, Makimura C, Koyama A, Fujita Y, Tsurutani J, Sakai K, Sakamoto R, Nishio K, Nakagawa K
Biomedical reports   7(4) 380-384   Oct 2017   [Refereed]
Takegawa N, Nonagase Y, Yonesaka K, Sakai K, Maenishi O, Ogitani Y, Tamura T, Nishio K, Nakagawa K, Tsurutani J
International journal of cancer   141(8) 1682-1689   Oct 2017   [Refereed]
Yanae M, Fujimoto S, Tane K, Tanioka M, Fujiwara K, Tsubaki M, Yamazoe Y, Morishima Y, Chiba Y, Takao S, Komoike Y, Tsurutani J, Nakagawa K, Nishida S
Journal of bone oncology   8 18-22   Sep 2017   [Refereed]
Nagashima Y, Yoshino S, Yamamoto S, Maeda N, Azumi T, Komoike Y, Okuno K, Iwasa T, Tsurutani J, Nakagawa K, Masaaki O, Hiroaki N
Molecular and clinical oncology   7(3) 359-366   Sep 2017   [Refereed]
Kawakami H, Tanizaki J, Tanaka K, Haratani K, Hayashi H, Takeda M, Kamata K, Takenaka M, Kimura M, Chikugo T, Sato T, Kudo M, Ito A, Nakagawa K
Investigational new drugs   35(4) 529-536   Aug 2017   [Refereed]
Matsuoka H, Yoshiuchi K, Koyama A, Makimura C, Fujita Y, Tsurutani J, Sakai K, Sakamoto R, Nishio K, Nakagawa K
International journal of behavioral medicine   24(4) 535-541   Aug 2017   [Refereed]
Hida T, Nokihara H, Kondo M, Kim YH, Azuma K, Seto T, Takiguchi Y, Nishio M, Yoshioka H, Imamura F, Hotta K, Watanabe S, Goto K, Satouchi M, Kozuki T, Shukuya T, Nakagawa K, Mitsudomi T, Yamamoto N, Asakawa T, Asabe R, Tanaka T, Tamura T
Lancet (London, England)   390(10089) 29-39   Jul 2017   [Refereed]
Hida T, Satouchi M, Nakagawa K, Seto T, Matsumoto S, Kiura K, Nokihara H, Murakami H, Tokushige K, Hatano B, Nishio M
Japanese journal of clinical oncology   47(7) 618-624   Jul 2017   [Refereed]
Lee CK, Davies L, Wu YL, Mitsudomi T, Inoue A, Rosell R, Zhou C, Nakagawa K, Thongprasert S, Fukuoka M, Lord S, Marschner I, Tu YK, Gralla RJ, Gebski V, Mok T, Yang JC
Journal of the National Cancer Institute   109(6)    Jun 2017   [Refereed]
Tamura T, Kiura K, Seto T, Nakagawa K, Maemondo M, Inoue A, Hida T, Yoshioka H, Harada M, Ohe Y, Nogami N, Murakami H, Kuriki H, Shimada T, Tanaka T, Takeuchi K, Nishio M
Journal of clinical oncology : official journal of the American Society of Clinical Oncology   35(14) 1515-1521   May 2017   [Refereed]
Hida T, Nishio M, Nogami N, Ohe Y, Nokihara H, Sakai H, Satouchi M, Nakagawa K, Takenoyama M, Isobe H, Fujita S, Tanaka H, Minato K, Takahashi T, Maemondo M, Takeda K, Saka H, Goto K, Atagi S, Hirashima T, Sumiyoshi N, Tamura T
Cancer science   108(5) 1000-1006   May 2017   [Refereed]
Yamazaki N, Takenouchi T, Fujimoto M, Ihn H, Uchi H, Inozume T, Kiyohara Y, Uhara H, Nakagawa K, Furukawa H, Wada H, Noguchi K, Shimamoto T, Yokota K
Cancer chemotherapy and pharmacology   79(4) 651-660   Apr 2017   [Refereed]
Tambo Y, Hosomi Y, Sakai H, Nogami N, Atagi S, Sasaki Y, Kato T, Takahashi T, Seto T, Maemondo M, Nokihara H, Koyama R, Nakagawa K, Kawaguchi T, Okamura Y, Nakamura O, Nishio M, Tamura T
Investigational new drugs   35(2) 217-226   Apr 2017   [Refereed]
Sakai K, Matsuoka H, Ohtake Y, Makimura C, Izumi H, Fujita Y, Otsuka M, Tsurutani J, Nishio K, Nakagawa K, Koyama A
Molecular and clinical oncology   6(3) 331-333   Mar 2017   [Refereed]
Yonesaka K, Hirotani K, von Pawel J, Dediu M, Chen S, Copigneaux C, Nakagawa K
Lung cancer (Amsterdam, Netherlands)   105 1-6   Mar 2017   [Refereed]
Shimizu T, Yonesaka K, Hayashi H, Iwasa T, Haratani K, Yamada H, Ohwada S, Kamiyama E, Nakagawa K
Cancer chemotherapy and pharmacology   79(3) 489-495   Mar 2017   [Refereed]
Manegold C, Dingemans AC, Gray JE, Nakagawa K, Nicolson M, Peters S, Reck M, Wu YL, Brustugun OT, Crinò L, Felip E, Fennell D, Garrido P, Huber RM, Marabelle A, Moniuszko M, Mornex F, Novello S, Papotti M, Pérol M, Smit EF, Syrigos K, van Meerbeeck JP, van Zandwijk N, Chih-Hsin Yang J, Zhou C, Vokes E
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer   12(2) 194-207   Feb 2017   [Refereed]
Matsuoka H, Kaneda H, Sakai K, Koyama A, Nishio K, Nakagawa K
Clinical lung cancer   18(1) e85-e87   Jan 2017   [Refereed]

Conference Activities & Talks

 
HER2 genomic amplification in circulating tumor DNA from patients with cetuximab-resistant colorectal cancer
Takegawa N, Yonesaka K, Sakai K, Ueda H, Watanabe S, Nonagase Y, Okuno T, Takeda M, Maenishi O, Tsurutani J, Satoh T, Okamoto I, Nishio K, Tamura T, Nakagawa K.
107th American Association for Cancer Research Annual Meeting, New Orleans, U.S.A.   2016   
Hergulin-induced resistance against HER2-targeted therapies in HER2 positive breast and gastric cancer in vitro and in vino
Nonagase Y,Yonesaka K, Kawakami H, Watanabe S, Haratani K, Takahama T, Takegawa N, Ueda H, Tanizaki J, Hayashi H, Yoshida T, Takeda M, Chiba Y, Tamura T, Nakagawa K, Tsurutani J.
107th American Association for Cancer Research Annual Meeting, New Orleans, U.S.A.   2016   
Antitumor activity of alectinib(CH5424802/RO542802)for ALK-rearranged NSCLC with or without prior crizotinib treatment in bioequivalence study
Kazuhiko Nakagawa,Toyoaki Hida,Miyako Satouchi,Makoto Nishino,Katsuyuki Hotta,Haruyasy Murakami,Yuichiro Ohe,Koji Takeda,Masahiro Tatuno,Naoki Yoshikawa,Tomohiro Tanaka,Tomohide Tamura
2014 ASCO Annual Meeting   2014   
Pooled safety analysis of EGFR-TKI therapy in patients with EGFR-mutated non-small cell lung cancer
Masayuki Takeda,Isamu Omoto,Kazuhiko Nakagawa
2014 ASCO Annual Meeting   2014   
What can WJOG and JCOG contribute to Japan-Taiwan phase I trials?
Nakagawa K
The 2nd Japan-Taiwan Oncology Phase I Conference(JTOPIC),Taipei.   2013   
MET amplification as a potential therapeutic target in gastric cancer.
Hisato Kawakami, IsamuOkamoto, TokuzoArao, Wataru Okamoto, Kazuko Matsumoto, Hirokazu Taniguchi, Kiyoko Kuwata, Haruka Yamaguchi, Kazuto Nishio, Kazuhiko Nakagawa, Yasuhide Yamada
104th American Association for Cancer Research Annual Meeting, Wshington D.C., U.S.A.   2013   
Differential roles of trans-phophorylated EGFR,HER2,HER3,and RET as heterodimerizoation partenrs of MET in lung cancer with MET amplification.
Tanizaki J, Okamoto I, Sakai K, Nakagawa K.
102rd American Association for Cancer Research Annual Meeting,   2012   
Chemotherapy with CPT-11 after gemcitabine failure in patients with advanced pancreatic cancer.
Kaneda H, Ueda S, Makimura C, Kiyota H, Oakmoto I, Tanaka K, Nishina S, Kudo T, Turutani J, Miyazaki M, FujisakaY, Okamoto W, Kirata T, Nakagawa K.
ESMO 14th World Congress on Gastrointestinal Cancer, Barcelona, Spain.   2012   
Second-Line chemotherapy with S-1 after Cisplatin and Gemcitabine failure in patients with advanced biliary tract cancer.
Ueda S,Nakagawa K.et al.
ESMO 14th World Congress on Gastrointestinal Cancer, Barcelona, Spain.   2012   
The history and current state of cultivation of medical oncologists in Japan
CSMO & CACO Special Forum:The history and current state of clinical oncologist training Nakagawa K,
The 6th Chinese Symposium on Medical Oncology(Beijing)   2012   
Indivualized therapy for lung cancer
Nakagawa K,
The 6th Chinese Symposium on Medical Oncology   2012   
Current Status of S1 in management of lung cancer
Nakagawa K
5th Asian Pacific Conference, (Hong Kong)   2012   
Results of a phase I dose escalation trial (WJOG3305) using accelerated hyperfractionated 3D-conformal radiation therapy (AHF-3DCRT) and concurrent chemotherapy for unresectable stage III Non-Small Cell Lung Cancer (NSCLC).
the 4th APLCC (Asia Pacific Lung Cancer Conference)   Dec 2010   the 4th APLCC (Asia Pacific Lung Cancer Conference)
A phase I study of chemoradiotherapy with use of three-dimensional conformal radiotherapy (3D-CRT) and accelerated hyperfractionation (AHF) for unresectable non-small-cell lung cancer (NSCLC): WJOG3305.
the 52nd Annual Meeting of the American Society for Therapeutic Radiology and Oncology   Nov 2010   the 52nd Annual Meeting of the American Society for Therapeutic Radiology and Oncology
Association of thymidylate synthase (TS) expression with response to S-1 plus carboplatin (CBDCA) in non-small cell lung cancer (NSCLC) patients (pts)
46th A.S.C.O   Jun 2010   46th A.S.C.O
IASLCWorkshop「Clinical trials for stageⅢ NSCLC」
Nov 2009   
A phase Ⅲ、first-line trial of gefitinib versus cisplatin plus docetaxel for patients with advanced or recurrent non-small cell lung cancer (NSCLC) harboring activating mutation of the epidermal growthfactor receptor (EGFR)
34th ESMO   Sep 2009   34th ESMO
Phase 1 study of sunitinib(SU) in combination with pemetrexed(Pem) in patients(pts) with advanced solid tumors(ST) 』
IASLC 13th World Conference on Lung Cancer   Aug 2009   IASLC 13th World Conference on Lung Cancer
Phase I Clinical and Biomarker Study of BIBF1120
45th Annual Meeting of the American Society of Clinical Oncology   Jun 2009   45th Annual Meeting of the American Society of Clinical Oncology
EGFR-RAS
Mar 2009   
EGFR-TKIs on Treatment in advanced NSCLC
International Congress on Anti-Cancer Treatment   Feb 2009   International Congress on Anti-Cancer Treatment
Phase III study of mitomycin/vindesine/cisplatin (MVP) vs. weekly irinotecan/carboplatin (IC) or weekly pacritaxel/carboplatin (PC) with concurrent thoracic radiotherapy (TRT) for unresectable stage III non-small cell lung cancer (WJTOG0105): special ref
the 51st Annual Meeting of the American Society for Radiation Oncology   2009   the 51st Annual Meeting of the American Society for Radiation Oncology
Phase I study of sunitinib(SU) in combination with pemetrexed(pem) in patients(pts) with advanced solid tumors(ST)
46th ASCO Annual Meeting   2009   46th ASCO Annual Meeting
Radiosensitizing effect of YM155,a novel small molecule survivin suppressant, in non-small cell lung cancer cell lines
A.A.C.R   Apr 2008   A.A.C.R
Matuzumab and cetuximab activateb the epidermal growth factor receptor but fail to trigger downstream signaling by akt or erk
A.A.C.R   Apr 2008   A.A.C.R
IMP-3 promotes cellular proliferation activity in gastric cancer
A.A.C.R   Apr 2008   A.A.C.R
The clinical development strategy for ixabepilone (BMS-247550)in patients with NSCLC
Asia-Pacific-Japan Lung Cancer Advisory Board   Oct 2007   Asia-Pacific-Japan Lung Cancer Advisory Board
Synergistic effects of S-1 and gefitinib by modulating the metabolic enzymes of 5-fluorouracil in NSCLC cell lines
Oct 2007   
Matuzumab and cetuximab activate the epidermal growth factor receptor but fail to trigger downstream signaling
66th Annual Meeting of the Japanese Cancer Association   Oct 2007   66th Annual Meeting of the Japanese Cancer Association
Suppression of SRPX2 mRNA expression inhibits cellular growth and adhesion in gastric cancer cells
66th Annual Meeting of the Japanese Cancer Association   Oct 2007   66th Annual Meeting of the Japanese Cancer Association
A Long-term Result by Hyperfractionated Radiotherapy with Concurrent Chemotherapy for Limited-stage Small Cell Lung Cancer (LD-SCLC): a Retrospective Analysis in a Single Institution.
12th World Conference on Lung Cancer   Sep 2007   12th World Conference on Lung Cancer
Prognostic factors affecting survival on pretreated patients with locally advanced or metastatic non-small cell lung cancer
The European Cancer Conference   Sep 2007   The European Cancer Conference
Manegement of Bone Metastases in Lung Cancer
Bisphosphonate International Symposium -New Strategy of Bisphosphonete in Lung Cancer   Jul 2007   Bisphosphonate International Symposium -New Strategy of Bisphosphonete in Lung Cancer
Phase I study of YM155, a first-in-class surviving suppressant, in patients with advanced solid tumors in Japan
43th A.S.C.O.   May 2007   43th A.S.C.O.
Differential constitutive activation of epidermal growth factor receptor(EGFR) in non-small-cell lung cancers bearing EGFR gene mutation and amplification
Dec 2006   
A phase I study of pemetrexed supplemented with folic acid (FA) and vitamin B12 (VB12) in Japanese patients with solid tumors.
Dec 2006   
Randomized phase II trial of irinotecan plus etoposide (IPE) every three weeks in patients with extensive disease small cell lung cancer (ED-SCLC)
Dec 2006   
Pharmacokinetics and safety of escalating doses of darbepoetin alfa (KRN321) in cancer patients undergoing myelosuppressive chemotherapy.
Dec 2006   
Phase I/II Trial of sequential chemoradiotherapy using a novel hypoxic cell radiosensitizer, doranidazole (PR-350), in patients (pts) with locally advanced non-small cell lung cancer (NSCLC)
the 48th Annual Meeting of the American Society for Therapeutic Radiology and Oncology   Nov 2006   the 48th Annual Meeting of the American Society for Therapeutic Radiology and Oncology
Relationship between EGFR protein expression, EGFR gene amplification, EGFR gene mutations and gefitinib sensitivity in human non-small cell lung cancer cell lines
97th American Association of Cancer Reserarch   Apr 2006   97th American Association of Cancer Reserarch
Dose intensive chemotherapy in advanced thymoma: report of Japan clinical oncology trials (JCOG9605 and 9606).
2006   
Randomized phase II study of carboplatin and paclitaxel (CP) versus gemcitabine and vinorelbine (GV) in performance status (PS) 2 patients with advanced non-small cell lung cancer (NSCLC): preliminary results of West Japan Thoracic Oncology Group 0004
31st ESMO   2006   31st ESMO
A randomized double-blind phase Ⅱa dose-finding study of ZD6474 in Japanese patients with NSCLC
ASCO Annual Meeting   2006   ASCO Annual Meeting
The present conditions and problems of molecule target drug
Mar 2005   
Emerging data to better understanding in EGFR-TKI therapy’-Japanese Clinical Experience of Gefitinib
The Thai Society of Clinical Oncology Annual Meeting Symposium   2004   The Thai Society of Clinical Oncology Annual Meeting Symposium
Synergistic antitumor activity of Geficinib, an epidermal growth factor receptor tyrosine kinase inhibitor, in combination with vinorelbine in human lung cancer
Jun 2003   
Clinical test in cancer therapy - The present condition and a problem in kinki University -
Mar 2003   
Phase I/II study of Nedaplatin and Gemcitabine for non-small cell lung cancer
Mar 2003   
Synergistic antitumor activity of Geftinib, an epidermal growth factor receptor tyrosine rainase inhibitor, in combination with vinorelbine in human lung cancer tenografts
Feb 2003   
Symposium「Molecular Target Therapy on Non-small Cell Lung Cancer」
The 1st International Symposium on CNS Germ Cell Tumor   2003   The 1st International Symposium on CNS Germ Cell Tumor
Targeted-therapy in NSCLC
IASLC Workshop of the current strategy for stage III-IV non-small cell lung cancer   Nov 2002   IASLC Workshop of the current strategy for stage III-IV non-small cell lung cancer
Thoracoscope with videoscop(LTF-240) under local auestheia
Nov 2002   
Phase I and pharmacokinetics Trial of BNP7787 in patients receiving cisplatin and paclitaxel for advanced Non-small Cell Lung Cancer(NSCLC)
14th EORTC-NCI-AACR symposium   Nov 2002   14th EORTC-NCI-AACR symposium
Phase I/II study of Nedaplatin plus Gemcitabine in patients with non-small cell lung cancer
Nov 2002   
A randomized trial in febrile neutropenic patients: cefezopran vs meropenem
Nov 2002   
A phase II study of weekly Paclitaxel in Patients with relopse small lung cancer
Nov 2002   
Retrospectine study of 2nd-line platinum chemotherapy in Advanced Non-Small Cell Lung Cancer patients post non-platinum chemotherapy
Nov 2002   
Two cases of bronchial foreign substances that were dental treatment implements
Nov 2002   
Clinical evaluation of a EGFR selective tyrosine kinase inhibitor, ZD1839
17th Workshop on France-Japan Cooperative Cancer Research Program   Oct 2002   17th Workshop on France-Japan Cooperative Cancer Research Program
Dose-finding study of weekly Irinotecan (CPT-11) and Carboplatin (CBDCA) with concurrent thoracic radiotherapy (TRT) in locally advanced non-small cell lung cancer (NSCLC)
27th ESMO Congress   Oct 2002   27th ESMO Congress
Background and rationale of new molecular targeted therapies - Japanese experience and point of view
8th Central European Lung Cancer Conference European-Japanese Joint Symposium   Sep 2002   8th Central European Lung Cancer Conference European-Japanese Joint Symposium
Usefulness of under computerized tomography scan radiography guided lung biopsy -compare with past under cpmputerized tomography scan guided lung biopsy
Aug 2002   
Medical thoracoscopy under local aneschesa with video-thoracoscope (LTF-240)
May 2002   
Risk factors of radiathion pheumonitis following chemoradiotherapy with CRP-11
The 38th AMERICAN SOCIETY OF CLINICAL ONCOLOGY   May 2002   The 38th AMERICAN SOCIETY OF CLINICAL ONCOLOGY
Risk factors of radiathion pheumonitis following chemoradiotherapy with CRP-11
May 2002   
Phase II study of weekly paclitaxel for relapsed small cell lung cancer.
ASCO   2002   ASCO
Symposium 「Is concurrent chemoradiotherapy superior to sequential chemoradiotherapy.」
Cross Chemoradiation in NSCLC   2002   Cross Chemoradiation in NSCLC
workshop「Clinical evaluation of a EGFR selective tyrosine kinase inhibitor, ZD1839 (Iressa?).」
17th Workshop on France-Japan Cooperative Cancer Research Program   2002   17th Workshop on France-Japan Cooperative Cancer Research Program
Symposium「Background and rationale of new molecular targeted therapies-Japanese experience and point of view.」
8th Central European Lung Cancer Conference European-Japanese Joint Symposium   2002   8th Central European Lung Cancer Conference European-Japanese Joint Symposium
Gene expression monitoring with cDNA array revealed the major biological targets of farnesyl transferase (FT) inhibitor, R115777 (ZarnestraTM), in a phase I, pharmacokinetic (PK) and pharmacodynamic (PD) study.
American Society of Clinical Oncology   2002   American Society of Clinical Oncology
Clinical evaluation of a EGFR selective tyrosine kinase inhibitor, ZD1839 (Iressa-).
18th Bristol-Myers Squibb Nagoya International Cancer Treatment Symposium   2002   18th Bristol-Myers Squibb Nagoya International Cancer Treatment Symposium
Symposium「EGFR tyrosine kinase inhibitors: Novel therapy in lung cancer」
Cancer Care Ireland   2002   Cancer Care Ireland
EGFR tyrosine kinase inhibitors: ZD1839 and ZD6474
The 7th International Symposium on Cancer Chemotherapy.   2002   The 7th International Symposium on Cancer Chemotherapy.
Phase III trial with docetaxel in advanced-NSCLC.
IASLC Workshop of the current strategy for stage III-IV non-small cell lung cancer   2002   IASLC Workshop of the current strategy for stage III-IV non-small cell lung cancer
Clinical evaluation of a selective EGFR tyrosin kinase inhibitor,Iressa,Experience and perspectives in Japan
Irland Cancer Care Meetin   2002   Irland Cancer Care Meetin
Phase I study of taxol, gemcitabine, and vinorelbine for solid tumors
Nov 2001   
Pharmacokinetic / pharmacodynamic study of weekly cisplatin plus docetaxel
Nov 2001   
Pharmacokinetic / pharmacodynamic study of weekly cisplatin plus docetaxel
Pilot study of trimodality therapy with chemotherapy+radiation+surgery to untreated limitted SCLC
Nov 2001   
Pilot study of weekly CPT-11 and CBDCA with concurrent thoracic radiotherapy in locally advanced non-small cell lung cancer
Sep 2001   
Comparison between 24hrCCr, Cockcroft and Jellife in Carboplatin clearance using Calvert method
Jul 2001   
A phase I study of weekly taxotere + cisplatin concurrent with theracic radiation therapy in patients with locally advanced NSCLC
Apr 2001   
Induction of MRP5/SMRP m RNA by adriamycin exposure and its overexpression in human lung cancer cells resistant to adriamycin.
AACR Annual Meeting   Mar 2001   AACR Annual Meeting
A phase I, pharmacokinetic (PK) and pharmacodynamic (PD) study of the farnesyl transferase inhibitor (FTI) R115777 in Japanese patients with advanced non-hematological malignancies.
2001 American Society Clinical Oncology meeting A317, 2001.   2001   2001 American Society Clinical Oncology meeting A317, 2001.
Phase I and pharmacokinetic study of CPT-11 and Taxol in patients with lung cancer.
2001   
Phase I and pharmacokinetic study of CPT-11 and Taxol in patients with lung cancer. 
2001   
A phase Ⅰ, pharmacokinetic (PK) and pharmacodynamic (PD) study of the farnesyl transferase inhibitor (FTI) R115777 in Japanese patients with advanced non-hematological malignancies
American Society of Clinical Oncology,   2001   American Society of Clinical Oncology,
Farnesy1 transferase inhibitor (FTI): R115777.
The 6th International Symposium on Cancer Chemotherapy   2001   The 6th International Symposium on Cancer Chemotherapy
Efficacy of chemotherapy for a patient with neuro-endocrine tumor of the color - a case report
Dec 2000   
A phase I study of ZD1839 for solid tumor
Nov 2000   
A phase II study of irinotecan (CPT-11) and doxorubicin (DXR) in patients with refractory or relapsed small-cell lung cancer (SCLC)
Nov 2000   
Clinical Development of Molecular Targed Drug in Cancer Chemotherapy
Oct 2000   
Randomized phase II study of docetacle plus cisplatin versus decetaxel plus irinotecan in advanced non-small cell lung cancer: A West Japan Oncology Study
25th Cogress of the European Society for Medical Oncology   Oct 2000   25th Cogress of the European Society for Medical Oncology
A phase I intermittent dose-escalation trial of ZD1839(IRESSA) in Japanese Patients with solid tumors
Oct 2000   
Pilot study of Trimodality Therapy for Untreated LD-Small-Cell Lung Cancer patients
Oct 2000   
A phase I Trial of Weekly Docetaxel (TXT) and Cisplatin (CDDP) Concomitant with Thoracic Radiation Therapy for Patients with Unresectable locally advanced non-small-Cell Lung Cancer
European society medical oncology congress2000   Oct 2000   European society medical oncology congress2000
A phase I trial of Weekly Paclitaxel in patient with reccurance refractly small cell lung cancer
Oct 2000   
Frequent adnormalities of TSG101 gene in non-small-cell lung cancer
Jul 2000   
Pilot study of Cisplatin (CDDP) and CPT-11 concurrent with Whole brain radiation therapy for patients with Unresectab Non-small Lung Cancer (NSCLC)
Jul 2000   
A Phase I study of Non-pratinum triplet regimen
Jun 2000   
A case of primary malignant melanoma of the esophagus with trachea and lung metastasis
Jun 2000   

Research Grants & Projects

 
Clinical developement of new anti-cancer drugs
Establishment of Lung cancer chemotherapy